WO 01/09170 - 18 - PCT/FR00/02174

CLAIMS

A peptide, characterized in that it consists of a 1. sequence which includes the juxtamembrane domain 5 of the cytoplasmic domain of amyloid precursor protein (βAPP) (one-letter code), and which are selected from the group consisting of Y, KQYTSIHHGY, (SEO sequences NO: 2), Y, KKQYTSIHHGY, (SEQ ID NO: 3) and Y, KKKQYTSIHHGY, (SEQ ID NO: 4), in which Yo is null or represents 10 V, VV, VVE VVEV or VVEVD and Y, represents an internalization and addressing peptide derived from the 3rd helix of homeodomains, and from structurally related peptides.


15

- 2. The peptide as claimed in claim 1, characterized that said internalization and addressing corresponds sequence peptide to the $X_1X_2X_3X_4X_5X_6X_7X_8X_9X_{10}X_{11}X_{12}X_{13}X_{14}X_{15}X_{16}$, in which 20 $X_{1}, X_{2}, X_{3}, X_{4}, X_{5}, X_{6}, X_{7}, X_{8}, X_{9}, X_{10}, X_{11}, X_{12}, X_{13}, X_{14}, X_{15}$ and X₁₆ each represent an α -amino acid, 6 to 10 of said amino acids being hydrophobic and X6 representing a tryptophan.
- 25 3. The peptide as claimed in claim 1 or claim 2, characterized in that the sequence Y_1 corresponds to the sequence KQIKIWFQNRRMKWKK (SEQ ID NO: 5).
- 4. The use of a peptide comprising the juxtamembrane domain of the cytoplasmic domain of amyloid precursor protein (APP), for selecting and screening products capable of inhibiting apoptosis.
- 35 5. The use as claimed in claim 4, characterized in that said peptide is combined with an internalization peptide selected from the group consisting of internalization peptides capable of crossing the blood-brain barrier.

- The use as claimed in either of claims 4 and 5, 6. characterized in that said peptide is selected from the group consisting of the sequences (one-5 letter code) Y,KQYTSIHHGY, (SEQ Y, KKQYTSIHHGY, (SEQ ID NO: 3) and Y, KKKQYTSIHHGY, (SEQ ID NO: 4), in which Yo is null or represents V, VV, VVE VVEV or VVEVD and Y, is null or internalization and addressing an derived the 3rd helix of 10 peptide from structurally related homeodomains, and from peptides.
- The use as claimed in any one of claims 4 to 6, 7. characterized in that said internalization peptide 15 the corresponds to sequence $X_1X_2X_3X_4X_5X_6X_7X_8X_9X_{10}X_{11}X_{12}X_{13}X_{14}X_{15}X_{16}$, which in $X_{1,1}X_{2,1}X_{3,1}X_{4,1}X_{5,1}X_{6,1}X_{7,1}X_{8,1}X_{9,1}X_{10,1}X_{11,1}X_{12,1}X_{13,1}X_{14,1}X_{15}$ and X_{16} each represent an α -amino acid, 6 to 10 of said amino acids being hydrophobic and X6 representing a 20 tryptophan.
- 8. The use of cells, into which a peptide as defined in claims 4 to 7 has been internalized, for selecting and screening products capable of inhibiting apoptosis.
- 9. A method for screening and selecting products capable of inhibiting apoptosis, characterized in that it comprises:
 - bringing the potential inhibitor into contact with a cell into which a peptide as defined in claims 4 to 7 has been internalized, and

35

- measuring cleavage of DNA or of actin or measuring the p20 subunit of caspase 3.



- 10. The use of a peptide as defined in claims 4 to 7, for preparing an anticancer medicinal product.
- 11. A peptide, characterized in that it is selected from the group consisting of the sequences (one-letter code) Y₁KQYTSIHHGY₀ (SEQ ID NO: 2) and Y₁KKQYTSIHHGY₀ (SEQ ID NO: 3), in which Y₀ is null or represents V, VV, VVE VVEV or VVEVD and Y₁ is null, and of the peptide of formula Y₁KKKQYTSIHHGY₀ (SEQ ID NO: 4), in which Y₀ represents VVEVD and Y₁ is null.